Cargando…
Macitentan Improves Risk Categorization for Liver Transplant Mortality in Patients With Portopulmonary Hypertension: A PORTICO Study Post Hoc Analysis
Autores principales: | Krowka, Michael, Cottreel, Emmanuelle, Hoeper, Marius M., Kim, Nick H., Martin, Nicolas, Sitbon, Olivier, Bosch, Jaume |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7383602/ https://www.ncbi.nlm.nih.gov/pubmed/32150762 http://dx.doi.org/10.1002/lt.25747 |
Ejemplares similares
-
Macitentan treatment of portopulmonary hypertension with hepatopulmonary syndrome: a case report and literature review
por: Li, Niuniu, et al.
Publicado: (2023) -
Macitentan in pulmonary arterial hypertension: The SERAPHIN trial
por: Said, Karim
Publicado: (2014) -
Portopulmonary hypertension
por: Saleemi, Sarfraz
Publicado: (2010) -
Variation in Bile Microbiome by the Etiology of Cholestatic Liver Disease
por: Tyc, Olaf, et al.
Publicado: (2020) -
Portopulmonary Hypertension: A Survey of Practice Patterns and Provider Attitudes
por: DuBrock, Hilary M., et al.
Publicado: (2019)